Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dorsal root ganglion single-cell RNA-seq dataset of painful diabetic peripheral neuropathy rat, diabeitc rats, and health rats

ABSTRACT: Painful diabetic peripheral neuropathy (PDPN) is a common complication of diabetes mellitus (DM). As one of the most disturbing symptoms, mechanical allodynia (MA) in PDPN remains largely unexplored. This dataset contains single-cell RNA sequencing results from rat dorsal root ganglion (DRG). The goal of this experiment was to investigate the transcriptional changes of distinct cell types in the DRG along MA development.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE176017 | GEO | 2021/12/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from the dorsal root ganglia during streptozotocin-induced painful diabetic neuropathy in rats

2011-11-30 | GSE34000 | GEO

Expression data from the dorsal root ganglia during streptozotocin-induced painful diabetic neuropathy in rats

Project description:FK1706 potentiated nerve growth factor-induced neurite outgrowth, putatively mediated via FKBP-52 and the Ras/Raf/MAPK signaling pathway. It also improved mechanical allodynia accompanied by the recovery of intraepidermal nerve fiber density in a painful diabetic neuropathy in rats. We analyzed gene expression of the dorsal root ganglia together with measurement of mechanical allodynia in diabetic rats to try to capture the global fingerprint of changes in gene expression associated with FK1706 administration and also to elucidate the putative mechanisms of its neurotrophic activity in vivo. Normal, STZ-treated controls, and STZ + FK1706 groups were used to evaluate gene expression analysis. Dorsal root ganglia from L4 to L6 were collected at the day after 1, 2, and 3 weeks of FK1706 administration, were immediately immersed in RNAlater reagent, and stored as instructed before RNA extraction. Equal amounts of total RNA from five rats were collected for each group.

2011-11-30 | E-GEOD-34000 | biostudies-arrayexpress

Dorsal root ganglion single-cell RNA-seq dataset of painful diabetic peripheral neuropathy rat, diabeitc rats, and health rats

Project description:Dorsal root ganglion single-cell RNA-seq dataset of painful diabetic peripheral neuropathy rat, diabeitc rats, and health rats

| PRJNA734592 | ENA

Single-cell transcriptome analysis reveals distinct cell populations in dorsal root ganglia and their potential roles in diabetic peripheral neuropathy

Project description:Diabetic peripheral neuropathy (DPN) is the most common form of neuropathy, and have considerable morbidity, which occurs in approximately 50% of diabetic patients. Here, we performed scRNA-seq technology using 10× Genomics sequencing on DRG tissues isolated from control and DPN rats, to identify the cell type composition of DRG, and to reveal the roles of different cell types in mediating DPN.

2023-11-23 | GSE248328 | GEO

The transcriptomic signature of painful and non-painful human NF2 schwannomas

Project description:The transcriptomic signature of painful and non-painful human NF2 schwannomas

| PRJNA575542 | ENA

The transcriptomic signature of painful and non-painful human NF2 schwannomas [set2]

Project description:Schwannomas are benign peripheral nerve sheath tumors that are associated with substantial morbidity including severe, persistent pain. Treatment, essentially limited to surgical resection, is associated with significant morbidity and for many patient’s efficacious treatment of tumor-related pain is not achievable. There is an urgent need to elucidate the molecular mechanisms underlying schwannoma-induced pain as a first step in development of new therapeutics. In this study, we performed next-generation RNASequencing on a small cohort of formalin fixed paraffin-embedded, painful, and non-painful schwannoma samples obtained from Neurofibromatosis type 2 (NF2) patients. Differential gene and isoform level expression analysis revealed significant transcriptomic differences between painful and non-painful tumors; differentially regulated genes included members of the fibroblast growth factor (FGF) family of genes. Using a xenograft model of human-NF2 we demonstrated that over-expression of FGF7 in schwannoma cells was associated with the development of pain-like behaviors. These results demonstrate both the value of RNASeq utilizing formalin fixed tissues and reveal a novel pathway responsible for neoplasm-associated pain.

2020-05-01 | GSE138346 | GEO

The transcriptomic signature of painful and non-painful human NF2 schwannomas [set1]

2020-05-01 | GSE138344 | GEO

αO-conotoxin GeXIVA[1,2] reduced neuropathic pain and changed gene expression in chronic oxaliplatin-induced neuropathy mice model

Project description:Chemotherapy induced peripheral neuropathy (CIPN) is a dose-limiting painful neuropathy that occurs commonly during cancer management, which often leads to the discontinuation of medication. Previous studies suggest that the α9α10 nicotinic acetylcholine receptor (nAChR) specific antagonist αO-conotoxin GeXIVA[1,2] is effective in CIPN models, however the related mechanisms remains unclear. Here we analyzed the preventive effect of GeXIVA[1,2] on neuropathic pain in the long-term oxaliplatin injection induced CIPN model. At the end of treatment, lumbar (L4-L6) spinal cord was extracted, and RNA-sequencing and bioinformatic analysis were performed to investigate the potential genes and pathways related to CIPN and GeXIVA[1,2]. GeXIVA[1,2] inhibited the development of mechanical allodynia induced by chronic oxaliplatin treatment. Repeated injections of GeXIVA[1,2] for 3 weeks have no effect on mice normal pain threshold or locomotor activity and anxiety-like behavior as evaluated in the open field test (OFT) and elevated plus maze (EPM). Our RNA-sequencing results identified 209 differentially expressed genes (DEGs) in CIPN model, simultaneously injection of GeXIVA[1,2] with oxaliplatin altered 53 of the identified DEGs. These reverted genes were significantly enriched in immune-related pathways represented by cytokine-cytokine receptor interaction pathway. Our findings suggest that GeXIVA[1,2] could be a potential therapeutic compound for chronic oxaliplatin induced CIPN management.

2024-01-18 | GSE253183 | GEO

The transcriptomic signature of painful and non-painful human NF2 schwannomas [set2]

Project description:The transcriptomic signature of painful and non-painful human NF2 schwannomas [set2]

| PRJNA575540 | ENA

The transcriptomic signature of painful and non-painful human NF2 schwannomas [set1]

Project description:The transcriptomic signature of painful and non-painful human NF2 schwannomas [set1]

| PRJNA575539 | ENA